Swixx Biopharma Acquisition, Valuation, Funding & Investors

Swixx Biopharma was acquired by SK Capital Partners and HBM Healthcare Investments for $1.6B in December 2025, a 1.7x multiple on $972M of revenue.

Swixx Biopharma acquisition price

$1.6B

Acquired by SK Capital Partners, HBM Healthcare Investments · Dec 2025

Swixx Biopharma revenue at acquisition

$972M

Last twelve months · Dec 2025

Swixx Biopharma revenue multiple at acquisition

1.7x

EV/Revenue · Dec 2025

Cumulative funding Swixx Biopharma raised

$98M

across 3 funding rounds

Swixx Biopharma Overview

About Swixx Biopharma

Swixx Biopharma is a pharmaceutical commercialization company that delivers medications to underserved and hard-to-reach markets, with operations in 45 countries across Europe, Eurasia, the Middle East, and Latin America. It focuses on rare disease, oncology-hematology, specialty care, vaccines, and self-medication products, acting as a commercialization partner for biotech and pharma companies seeking access to complex emerging markets. The company employs more than 1,600 people and was co-founded by Stuart Swanson and Petr Nemec.


Founded

2014

HQ

SwitzerlandSwitzerland

Status

Acquired

Customer focus

B2B

Revenue model

Services

Revenue

$972M (Dec 2025)

Valuation

$1.6B (acquired Dec 2025)

Swixx Biopharma Acquisition

Swixx Biopharma was acquired by SK Capital Partners and HBM Healthcare Investments for $1.6B on 15 December 2025.

The acquisition price implies a 1.7x revenue multiple on $972M of revenue.

Before the acquisition Swixx Biopharma had raised $98M across 3 funding rounds.

Swixx Biopharma AG operates as the global leader in rest-of-world pharmaceutical commercialization services, delivering innovative, life-saving medications to underserved and hard-to-reach markets, with a presence in 45 countries across Europe, Eurasia, the Middle East, and Latin America. The company focuses on rare disease, oncology-hematology, specialty care, vaccines, and self-medication, expecting sales to exceed €1.3 billion in 2026 and over 1,600 employees by end of 2025. SK Capital Partners, a New York-based private investment firm focused on life sciences, specialty materials, and ingredients sectors managing approximately $10 billion in assets, announced a definitive agreement on December 15, 2025, to acquire a majority stake in Swixx, valuing the company in excess of €1.5 billion. Existing shareholders, including co-founders Stuart Swanson and Petr Němec, CEO Jean-Michel Lespinasse, CFO Petr Pipal, HBM Healthcare Investments (a 25.1% holder since 2017 with €26 million invested), and Mérieux Equity Partners, will retain significant minority stakes post-transaction. The strategic investment aims to accelerate Swixx's next phase of growth, global expansion, and role as a trusted multi-regional commercialization partner for biotech and pharma companies in complex emerging markets, with senior management remaining in place. Closing is expected in the first half of 2026, subject to customary regulatory approvals, with legal advisors including Walder Wyss for Swixx shareholders and Wolf Theiss for SK Capital across multiple jurisdictions. The deal provides Swixx with additional capital and SK Capital's deep industry expertise to enhance strategic positioning, drive sustainable growth, profitability, and patient access to essential medications, marking a pivotal moment amid its rapid scaling as one of the fastest-growing independent biopharma platforms.

Swixx Biopharma acquisition details
AcquirerDateTypePriceEV/Revenue
15 Dec 2025PE buyout$1.6B1.7x

Swixx Biopharma Funding History

Swixx Biopharma has raised a total of $98M across 3 funding rounds.

Swixx Biopharma's first fundraising round was a $21M undisclosed-stage round in April 2017. The most recent completed round was a $55M undisclosed-stage round in May 2021.

Swixx Biopharma funding rounds

Swixx Biopharma funding rounds
DateStageInvestorsRaisedDeal Summary
May 2021Undisclosed stageMérieux Equity Partners (lead); HBM Healthcare Investments$55M-
Apr 2017Undisclosed stageHBM Healthcare Investments (lead)$22MAmicus SA is a Switzerland-based company specializing in the distribution of pharmaceutical products, medical equipment, and over-the-counter brands in Central and Eastern Europe (CEE), particularly in markets where originators like Alcon, Bristol Myers Squibb, Cardinal Health, Expanscience, Grupo Ferrer, General Electric, Genexo, Pfizer, PharmaNutra, and Salvat Biotech choose not to maintain a direct presence. The company is revenue-generating and accelerates growth in its pharmaceutical business with this financing. Founded by executives with prior experience at Bristol-Myers Squibb affiliates in CEE, Amicus positions itself as an alternative partner for healthcare companies avoiding direct marketing and distribution in the region. On April 27, 2017, HBM Healthcare Investments announced a EUR 20 million equity investment in two tranches into the privately held Amicus SA, described as growth capital and a significant minority stake. HBM, a respected investor in pharma and biotech, became a keystone shareholder while Amicus founders and senior executives retained majority ownership. HBM had previously been a significant shareholder in PharmaSwiss SA, sold in 2011, linking back to some Amicus team members. The funds enable Amicus to accelerate portfolio growth, expand geographical reach, enhance corporate governance, and leverage HBM's network. Petr Nemec, Founding Partner, and Jean-Michel Lespinasse, CEO, highlighted HBM's value in contacts, ideas, and positioning for expansion.
Apr 2017Undisclosed stageHBM Partners (lead)$21MHBM committed EUR 20 million of growth capital in two tranches to the Swiss pharmaceutical services group then trading as Amicus SA. The money funded expansion of the company's representation business across Central and Eastern Europe, where it runs country operations on behalf of drug makers that do not maintain their own affiliates. The company was renamed Swixx BioPharma SA in May 2019.

Who has invested in Swixx Biopharma?

3 investors have backed Swixx Biopharma across its funding rounds, including HBM Healthcare Investments, Mérieux Equity Partners and HBM Partners.

Lead investors include Mérieux Equity Partners, HBM Healthcare Investments and HBM Partners.


Swixx Biopharma Investors

Investors in Swixx Biopharma by funding rounds participated
InvestorHQRoundsRoleFirst check
HBM Healthcare InvestmentsSwitzerlandZug2LeadApr 2017

This data is available for Pro users. Sign up to see all 3 Swixx Biopharma investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by Swixx Biopharma

Swixx Biopharma has acquired 1 company to date.

Last acquisition by Swixx Biopharma was on May 22nd 2024. Swixx Biopharma acquired Biopas for undisclosed valuation.


Latest Acquisitions by Swixx Biopharma

Biopas
Description
Biopas is a Mexico City-headquartered biopharmaceutical firm distributing specialty drugs for oncology, neurology, and rare diseases across Latin America. It markets products like kinase inhibitors and monoclonal antibodies through subsidiaries in Colombia, Peru, and Chile. Founded in 1998, Biopas partners with global players such as Pfizer and Novartis for market access in the region.
HQ CountryColombia
HQ City
Bogotá
Deal Date22 May 2024
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Swixx Biopharma acquisitions and their M&A valuation multiples.

Start Free Trial

Swixx Biopharma Competitors

Swixx Biopharma competitors include listed companies like Jubilant Pharmova and Bora Pharmaceuticals, and private ones like BioRay Pharmaceuticals, Belief BioMed, Letu and Sonoma Biotherapeutics.

Public and private companies comparable to Swixx Biopharma
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Jubilant PharmovaIndiaIndiaPublicly listed$858M$128M$1.7B2.1x
Bora PharmaceuticalsTaiwanTaiwanPublicly listed$597M$215M$1.7B3.2x
BioRay PharmaceuticalsChinaShanghaiPrivate$131M-$1.9B14.5x
Belief BioMedChinaShanghaiPrivate--$1.3B-
LetuChinaShenzhenPrivate--$1.1B-
Sonoma BiotherapeuticsUnited StatesSan Francisco, CAPrivate--$732M-

Swixx Biopharma Public Comps

Swixx Biopharma is no longer listed, but its public comps include AnaptysBio, Hualan Biological Vaccine, Eton Pharmaceuticals, InventisBio, Forte Biosciences, Idorsia, Cheezheng Tibetan Medicine, Concord Biotech, Syngene and Novavax.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
AnaptysBio$235M$56M5.8x10.1x24.2x34.4x
Hualan Biological Vaccine$179M$49M7.3x6.6x26.8x28.6x
Eton Pharmaceuticals$80M$3M20.4x12.7x509.7x40.6x
InventisBio$6M($49M)254.6x92.6x(29.1x)(32.7x)
Forte Biosciences-($71M)--(20.3x)-
Idorsia$268M($55M)11.6x11.7x(56.1x)(51.1x)
Cheezheng Tibetan Medicine$360M$137M3.8x-10.0x-
Concord Biotech$109M$43M14.2x12.7x35.7x35.6x

This data is available for Pro users. Sign up to see all Swixx Biopharma competitors and their valuation data.

Start Free Trial

Common questions about Swixx Biopharma

When was Swixx Biopharma founded?Swixx Biopharma was founded in 2014.
Where is Swixx Biopharma headquartered?Swixx Biopharma is headquartered in Switzerland.
Is Swixx Biopharma publicly listed?No, Swixx Biopharma was acquired by SK Capital Partners and HBM Healthcare Investments in December 2025.
Who acquired Swixx Biopharma?Swixx Biopharma was acquired by SK Capital Partners and HBM Healthcare Investments in December 2025.
How much was Swixx Biopharma acquired for?Swixx Biopharma was acquired for $1.6B in December 2025, a 1.7x revenue multiple.
How much funding has Swixx Biopharma raised?Swixx Biopharma has raised $98M across 3 funding rounds.
What was Swixx Biopharma's last funding round?Swixx Biopharma's last funding round was a $55M undisclosed-stage round in May 2021, led by Mérieux Equity Partners.
Who are Swixx Biopharma's investors?Swixx Biopharma's investors include HBM Healthcare Investments, Mérieux Equity Partners and HBM Partners.
Which companies are comparable to Swixx Biopharma?Companies comparable to Swixx Biopharma include Jubilant Pharmova, Bora Pharmaceuticals, BioRay Pharmaceuticals, Belief BioMed, Letu and Sonoma Biotherapeutics.
How many companies has Swixx Biopharma acquired?Swixx Biopharma has acquired 1 company, including Biopas.

See companies similar to Swixx Biopharma

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial